N-(Toluene-4-sulfonyl)sarcosyl-β-(N-benzylpiperidin-4-yl)-D,L-alanine | 220176-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(Toluene-4-sulfonyl)sarcosyl-β-(N-benzylpiperidin-4-yl)-D,L-alanine
• 英文别名: 3-(1-Benzylpiperidin-4-yl)-2-[[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]propanoic acid
• CAS: 220176-97-6
• 化学式: C₂₅H₃₃N₃O₅S
• 分子量: 487.62
• InChiKey: FBVBNHQKBVPJPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：——

  公开号：US20030065185A1

  公开（公告）日：2003-04-03

  Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及能够结合VLA-4的化合物。其中某些化合物还能够抑制白细胞粘附，尤其是通过VLA4介导的白细胞粘附。这类化合物在哺乳动物患者（例如人类）中治疗炎症性疾病非常有用，如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血等。这些化合物也可用于治疗炎症性脑疾病，如多发性硬化。
• DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1001971A1

  公开（公告）日：2000-05-24
• US6423688B1
  申请人：——

  公开号：US6423688B1

  公开（公告）日：2002-07-23
• US7288526B2
  申请人：——

  公开号：US7288526B2

  公开（公告）日：2007-10-30
• [EN] DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4<br/>[FR] COMPOSES DE DIPEPTIDES ET ASSOCIES INHIBANT UNE ADHESION DE LEUCOCYTES REGULEE PAR VLA-4
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：WO1999006432A1

  公开（公告）日：1999-02-11

  (EN) Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brains diseases such as multiple sclerosis.(FR) L'invention concerne des composés se liant à VLA-4. Certains de ces composés inhibent également une adhésion de leucocytes et, notamment, une adhésion de leucocytes régulée par VLA-4. Ces composés s'utilisent dans le traitement d'affections inflammatoires chez un patient mammalien, par exemple un humain, l'affection consistant par exemple en asthme, maladie d'Alzheimer, athérosclérose, syndrome démentiel du SIDA, diabète, affection intestinale inflammatoire, polyarthrite rhumatoïde, transplantation de tissus, métastase tumorale et ischémie myocardique. Les composés peuvent également être administrés pour le traitement d'affections cérébrales inflammatoires telles que la sclérose en plaques.